Deciphering Oocyte Factors That Can Reprogram Adult Cells
News Jul 04, 2018 | Original story sourced from Mary Ann Liebert, Inc.
The promise of generating truly pluripotent stem cells from terminally differentiated adult cell types continues to captivate scientists who envision great potential for therapeutic interventions. The two primary methods involve either the replacement of oocyte nuclei with adult somatic cell nuclei—a process known as somatic cell nuclear transfer (SCNT)—or the introduction, typically by viruses, of a cocktail of specific transcription factors to create induced pluripotent stem cells (iPSCs).
SCNT is more efficient and less variable, but technically more demanding. Further, the availability of high-quality oocytes is limited. Therefore, the potential to combine these approaches by identifying the crucial factors in oocytes that mediate SCNT efficiency is reviewed in a new article published in Stem Cells and Development.
In “Somatic Cell Reprogramming Informed by the Oocyte,” the authors categorically describe the known and potential oocyte-specific factors that can drive or assist somatic cell reprogramming by modulating the epigenetic landscape.
They sort these factors into maternal histones and their chaperones, histone deacetylases and acetyltransferases, histone methylation modifiers, DNA methylation modifiers, transcription factors, miRNAs, and lncRNAs. Specific epigenetic modifications known to influence pluripotency are discussed along with their disruption by small molecules.
Collectively, the authors provide a logical framework for understanding how oocyte factors can de-differentiate committed cells and a platform for studying and discovering optimal combinations to increase the efficiency, reproducibility, and safety of this technique.
“Elena González-Muñoz and Jose Cibelli provide an insightful treatise on recent advances in animal cloning and how those studies inform our understanding of induced pluripotency of somatic cells”. says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
This article has been republished from materials provided by Mary Ann Liebert, Inc. Note: material may have been edited for length and content. For further information, please contact the cited source.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.